Sort by
Keyphrases
Induced Apoptosis
100%
Imatinib Therapy
100%
K562 Cells
100%
BCR-ABL Fusion Gene
100%
MiR-30e
100%
Chronic Myeloid Leukemia
57%
Tyrosine Kinase Inhibitor
28%
Myeloid Leukemia Cells
28%
Gene Expression
14%
Therapeutic Efficacy
14%
Hematopoietic Stem Cells
14%
Bioinformatics Analysis
14%
Cancer Progression
14%
Tumor Suppressor
14%
Clinical Practice
14%
Expression Profile
14%
MiRNA Expression
14%
MicroRNA
14%
Leukemia Cell Lines
14%
Proliferation Apoptosis
14%
Treatment Choice
14%
Imatinib
14%
Leukemia Patients
14%
Non-coding
14%
3′-untranslated Region (3′-UTR)
14%
Patient Samples
14%
Cancer Development
14%
Role in Cancer
14%
Putative Targets
14%
Luciferase Assay
14%
Regulatory RNA
14%
BCR-ABL Expression
14%
Control Genes
14%
Abl Kinase
14%
Philadelphia Chromosome
14%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
K562 Cells
100%
Programmed Cell Death
100%
Imatinib
100%
MicroRNA
50%
Tyrosine Kinase Inhibitor
50%
Luciferase
25%
RNA
25%
Upregulation
25%
Kinase
25%
Phosphotransferase
25%
Carcinogenesis
25%
Tumor Suppressor Protein
25%
Fusion Gene
25%
Untranslated Region
25%
Gene Expression Control
25%
ABL (Gene)
25%
Philadelphia Chromosome
25%
Hematopoietic Cell
25%
Bioinformatics
25%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Chronic Myeloid Leukemia
100%
BCR ABL Protein
100%
microRNA
50%
Protein Tyrosine Kinase Inhibitor
50%
Diseases
50%
Luciferase
25%
Combination Therapy
25%
Malignant Neoplasm
25%
Phosphotransferase
25%
Carcinogenesis
25%
Philadelphia 1 Chromosome
25%
Tumor Suppressor Protein
25%